.png)
.png)
BioIVT to Host ADME-Tox Symposium in Basel, Switzerland
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it will host a symposium entitled “Innovative Models for ADME-Tox Research” at Hotel Odelya in Basel, Switzerland on June 22.
“We are delighted to have this opportunity to meet with our biopharmaceutical colleagues in person,” said Jeremy Clarke, Senior Director of Business Development, at BioIVT. “The pandemic proved how resourceful and flexible we can be, as an industry, when necessary to continue the important R&D work that we do. But there really is no good substitute for meeting in person to share research ideas and explore new ways of collaborating.”
Situated in a large private park, the Hotel Odelya is an ideal setting for symposium attendees to share scientific knowledge, network and discuss potential collaborations in a relaxed outdoor setting.
“I am looking forward to hearing how colleagues have used BioIVT hepatic products in novel ways to address unique research problems,” said Scott Heyward, Director of Research and Development at BioIVT. “We believe that BioIVT has the best-in-class platform technologies, but it is always exciting to see customers take our products and models and use them to develop new applications.”
BioIVT’s HEPATOPAC® technology is used extensively in ADME-Tox research because it incorporates metabolic, regulatory, and transporter function to better recapitulate in vivo conditions.
Scott Heyward will open the symposium by describing new applications for the HEPATOPAC long-term liver model. They include a steatosis model for fatty liver disease and the use of small interfering RNA to knockdown the expression of individual genes in HEPATOPAC cultures.
Then, Kenichi Umehara, PhD, Senior Principal Scientist at Roche Pharmaceutical Research, will explain how he used HEPATOPAC cultures to estimate the fraction of a drug metabolized by Cytochrome P450 (CYP) enzymes compared to hepatic metabolism for low clearance compounds.
Julia Riede, PhD, Principal Scientist at Novartis, will describe how she employed primary human hepatocyte spheroids as an in vitro tool for investigating drug compounds with low hepatic clearance.
In the afternoon, Kenneth R. Brouwer, PhD, RPh, Vice President of Technology, ADME-Tox at BioIVT will discuss the regulation of transporter expression and function in polarized hepatocyte models using FXR regulation of bile acid transport as an example.
Then, Melina Malinen, PhD, Senior Scientist at Orion Corporation will outline how she used transporter certified, sandwich-cultured human hepatocytes to investigate the organic solute transporter (OSTα/β) as a bile acid and drug transporter.
Additional information about this complimentary symposium is available at https://info.bioivt.com/basel-event.
“We are delighted to have this opportunity to meet with our biopharmaceutical colleagues in person,” said Jeremy Clarke, Senior Director of Business Development, at BioIVT. “The pandemic proved how resourceful and flexible we can be, as an industry, when necessary to continue the important R&D work that we do. But there really is no good substitute for meeting in person to share research ideas and explore new ways of collaborating.”
Situated in a large private park, the Hotel Odelya is an ideal setting for symposium attendees to share scientific knowledge, network and discuss potential collaborations in a relaxed outdoor setting.
“I am looking forward to hearing how colleagues have used BioIVT hepatic products in novel ways to address unique research problems,” said Scott Heyward, Director of Research and Development at BioIVT. “We believe that BioIVT has the best-in-class platform technologies, but it is always exciting to see customers take our products and models and use them to develop new applications.”
BioIVT’s HEPATOPAC® technology is used extensively in ADME-Tox research because it incorporates metabolic, regulatory, and transporter function to better recapitulate in vivo conditions.
Scott Heyward will open the symposium by describing new applications for the HEPATOPAC long-term liver model. They include a steatosis model for fatty liver disease and the use of small interfering RNA to knockdown the expression of individual genes in HEPATOPAC cultures.
Then, Kenichi Umehara, PhD, Senior Principal Scientist at Roche Pharmaceutical Research, will explain how he used HEPATOPAC cultures to estimate the fraction of a drug metabolized by Cytochrome P450 (CYP) enzymes compared to hepatic metabolism for low clearance compounds.
Julia Riede, PhD, Principal Scientist at Novartis, will describe how she employed primary human hepatocyte spheroids as an in vitro tool for investigating drug compounds with low hepatic clearance.
In the afternoon, Kenneth R. Brouwer, PhD, RPh, Vice President of Technology, ADME-Tox at BioIVT will discuss the regulation of transporter expression and function in polarized hepatocyte models using FXR regulation of bile acid transport as an example.
Then, Melina Malinen, PhD, Senior Scientist at Orion Corporation will outline how she used transporter certified, sandwich-cultured human hepatocytes to investigate the organic solute transporter (OSTα/β) as a bile acid and drug transporter.
Additional information about this complimentary symposium is available at https://info.bioivt.com/basel-event.